Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.28 USD | -2.29% | -0.57% | +6.35% |
Apr. 29 | RBC Capital Adjusts Price Target on Avantor to $30 From $29, Maintains Outperform Rating | MT |
Apr. 29 | Baird Trims Price Target on Avantor to $26 From $27, Maintains Outperform Rating | MT |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an expected P/E ratio at 35.69 and 25.54 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.35% | 16.49B | B | ||
-4.66% | 183B | C+ | ||
-1.01% | 108B | C | ||
-4.20% | 67.51B | A | ||
+2.68% | 50.67B | B- | ||
+9.12% | 44.7B | B- | ||
+2.41% | 40.95B | B+ | ||
+4.13% | 26.71B | A- | ||
+3.31% | 26.8B | B | ||
+12.66% | 24.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AVTR Stock
- Ratings Avantor, Inc.